Griffin HospitalGriffin Hospital Facebook ad: “Pluvicto Theranostics Program at the Griffin Health…”
Ran for 184 days, from November 25, 2025 to May 28, 2026, the last day Crush saw it.
Run by Griffin Hospital on Facebook. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 1531031428042052
- Platforms
- Facebook and Instagram
- Relaunches
- 0
Ad text
Exceptional, Advanced Prostate Cancer Care Griffin Health recently launched a Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) Theranostics program in its Nuclear Medicine Department, expanding access to a groundbreaking treatment option for patients with advanced prostate cancer. Developed by Novartis, Pluvicto is a FDA-approved radioligand therapy for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. This therapy targets prostate-specific membrane antigen (PSMA)-positive cancer cells, delivering a radioactive payload directly to the tumor, while minimizing damage to surrounding healthy tissue. For more information, visit www.griffinhealth.org/pluvicto.
Where the ad sends people
griffinhealth.org
Pluvicto Theranostics Program at the Griffin Health Nuclear Medicine, Molecular Imaging and Theranostics Department
Griffin Health Nuclear Medicine offers a groundbreaking treatment option for patients with advanced prostate cancer with its Pluvicto® Theranostics Program. Pluvicto is an FDA-approved radioligand therapy for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostat...
Learn more: griffinhealth.org(opens in a new tab)
